Last Updated : April 29, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
|---|---|---|---|---|---|---|
| Mavenclad | cladribine | Multiple Sclerosis, relapsing-remitting | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ozanex | ozenoxacin | Impetigo | Do not reimburse | Complete | ||
| Biktarvy | bictegravir/emtricitabine/tenofovir alafenamide | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opdivo in combination with Yervoy | Nivolumab in combination with Ipilimumab | Advanced or Metastatic Renal Cell Carcinoma (RCC). | Reimburse with clinical criteria and/or conditions | Complete | ||
| Gazyva | Obinutuzumab | Follicular Lymphoma (previously untreated) | Do not reimburse | Complete | ||
| Erleada | Apalutamide | non-metastatic castrate resistant prostate cancer (nm-CRPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xarelto | Rivaroxaban | Prevention of stroke and cardiovascular events in coronary and peripheral artery disease. | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opdivo | Nivolumab | Metastatic Hepatocellular Carcinoma (HCC) | Do not reimburse | Complete | ||
| Perjeta-Herceptin Combo Pack | Pertuzumab-Trastuzumab Combo Pack | Early Breast Cancer | Do not reimburse | Complete | ||
| Aermony RespiClick | fluticasone propionate | Asthma | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 29, 2024